A regulatory requirement non-interventional study to monitor the safety and effectiveness of Jardiance® (empagliflozin, 10mg) in Korean patients with chronic heart failure (NYHA class II-IV) First published 09/12/2021 Last updated 02/07/2025 EU PAS number:EUPAS44641 Study Ongoing